Female participants must not be pregnant and/or lactating

Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent mandatory ventilation (IMV), or are ineligible for IMV

Have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study

Are moribund irrespective of the provision of treatments

Have a known history or show evidence of human immunodeficiency virus (HIV) and/or hepatitis

Have recently undergone major surgery or central venous access device placement

Have a significant bleeding disorder or active vasculitis

Have experienced a thromboembolic event

Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia

Have a serious, nonhealing wound, peptic ulcer, or bone fracture

Have liver cirrhosis

Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins

Have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

A Study of LY3127804 in Participants With COVID-19